Publikationen in Zusammenarbeit mit Forschern von National Cancer Center Hospital (16)

2023

  1. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

    The Lancet, Vol. 402, Núm. 10395, pp. 41-53

  2. Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.

    Journal of Clinical Oncology

  3. Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer

    Cancer Science, Vol. 114, Núm. 3, pp. 1026-1036

2022

  1. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

    The Lancet Oncology, Vol. 23, Núm. 5, pp. 659-670

2021

  1. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 5, pp. 665-677

2020

  1. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials

    Annals of Oncology, Vol. 31, Núm. 1, pp. 88-95

  2. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer

    New England Journal of Medicine, Vol. 383, Núm. 23, pp. 2207-2218

2019

  1. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study

    Annals of Oncology, Vol. 30, Núm. 1, pp. 124-131

2018

  1. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

    Annals of Oncology, Vol. 29, Núm. 3, pp. 602-609

  2. Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: Exploratory analyses of the RAISE trial and validation in an electronic medical record data set

    ESMO Open, Vol. 3, Núm. 3

2017

  1. Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial

    European Journal of Cancer, Vol. 78, pp. 61-69

  2. Exposure–response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial

    Cancer Chemotherapy and Pharmacology, Vol. 80, Núm. 3, pp. 599-608

  3. Proxies of quality of life in metastatic colorectal cancer: Analyses in the RECOURSE trial

    ESMO Open, Vol. 2, Núm. 5

2016

  1. Subgroup analysis in RAISE: A randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression

    Annals of Oncology, Vol. 27, Núm. 11, pp. 2082-2089

2015

  1. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study

    The Lancet Oncology, Vol. 16, Núm. 5, pp. 499-508

  2. Randomized trial of TAS-102 for refractory metastatic colorectal cancer

    New England Journal of Medicine, Vol. 372, Núm. 20, pp. 1909-1919